Open-Label Placebo for Pain Management After Periacetabular Osteotomy
(COLP PAO Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
In this randomized controlled trial, 64 participants undergoing PAO at UCSF will be enrolled and randomized to receive either COLP plus treatment as usual (TAU) or TAU alone. Patients in the COLP arm will receive placebo pills alongside prescribed opioids and at scheduled intervals, beginning on postoperative day one. Weekly follow-up will be conducted for six weeks postoperatively via remote surveys and video visits.
Who Is on the Research Team?
Mohammad Diab, MD
Principal Investigator
University of California, San Francisco
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either COLP plus treatment as usual or treatment as usual alone, starting on post-operative day 1
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Open-Label Placebo
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Treatment As Usual (TAU) participants will receive their standard opioid dose, 5mg Oxycodone pill, three times a day beginning on post-operative day 1.
One placebo tablet will be taken with each oral opioid dose, 5mg Oxycodone, 3 times per day, beginning on post-operative day 1.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, San Francisco
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.